CRP and breast carcinoma: In this sense, as I-CRP did in T-ALL and breast cancer cell lines, chemotherapeutics such as anthracyclines and oxaliplatin can induce P-eIF2α in U2OS and HCT 116 cancer cells (Bezu et al., 2018[4]).